ClinicalTrials.gg
CompletedNCT04265911Updated May 2, 2022

Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects

A Phase 1 interventional study of ASP3772 (subcutaneous) and ASP3772 (intramuscular) in Healthy Volunteers, sponsored by Affinivax, Inc.. Completed at 1 site in Japan. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-02.

Sponsored by Affinivax, Inc. (part of GlaxoSmithKline) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Primary completion was Nov 2020, 6 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
20 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly to Japanese healthy adults 20 to 49 years of age.

This study will also evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly, in comparison to the active comparator 23-valent pneumococcal polysaccharide vaccine (PPSV23) in Japanese elderly subjects 65 to 85 years of age.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Pneumococcal vaccine
  • ASP3772
03

In context

Lead sponsor

Affinivax, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted before Affinivax, Inc. became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group 1: Subject is a healthy male or female between 20 and 49 years of age inclusive, at .
  • Group 2: Subject is a male or female between 65 and 85 years of age inclusive, at informed consent who is healthy or has chronic controlled, stable disease with no change in disease severity, medical therapy and no hospitalization history in last 12 weeks from informed consent as determined by medical history, physical examination, and laboratory data.
  • Female subject of non-; male subject not able to father children or who is able to father children and willing to use a highly effective method of .
  • Subject agrees not to participate in another interventional study while participating in the present study.
  • Subject has a (BMI) range of 17.6 to 26.4 kg/m\^2 inclusive in Group 1 and 15.4 to 28.6 kg/m\^2 inclusive in Group 2, and body weight at least 50 kg for male and 40 kg for female at screening.

Exclusion criteria

Exclusion Criteria:

  • Subject has had previous vaccination with any licensed or pneumococcal vaccine at any time.
  • Subject has a history of microbiologically-proven invasive disease caused by Streptococcus pneumoniae.
  • Subject has an immune disorder(s) (including disease), clinical conditions requiring drugs and/or a close relative who has congenital immunodeficiency.
  • Group 1: Subject has any illness that requires medication or treatment.
  • Group 2: Subject has any evidence of unstable or active cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease, e.g., uncontrolled hypertension, uncontrolled diabetes, heart failure, uncontrolled , end-stage renal disease, which is active and requires treatment.
  • Subject has any clinically significant history of allergic conditions including drug allergies, asthma or anaphylactic reactions, but excluding untreated asymptomatic seasonal allergies just before study vaccine administration.
  • Subject has a positive serology test for surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis A virus antibodies (immunoglobulin M), virus antibodies (anti-HCV) or antigens/antibodies to (HIV) type 1 and/or type 2 at screening.
  • Subject has/had febrile illness or symptomatic of viral, bacterial (including upper respiratory infection) or fungal (excluding skin infection) infection within 7 days prior to day 1.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    ASP3772 (subcutaneous) in Adults

    Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.

    Biological: ASP3772 (subcutaneous)

  • Experimental
    ASP3772 ((intramuscular) in Adults

    Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels.

    Biological: ASP3772 (intramuscular)

  • Experimental
    ASP3772 (subcutaneous) in Elderly

    Participants will receive a single dose of ASP3772 administered as an subcutaneous injection on Day 1 at one of three dose levels.

    Biological: ASP3772 (subcutaneous)

  • Experimental
    ASP3772 (intramuscular) in Elderly

    Participants will receive a single dose of ASP3772 administered as an intramuscular injection on Day 1 at one of three dose levels

    Biological: ASP3772 (intramuscular)

  • Active comparator
    PPSV23 (subcutaneous) in Elderly

    Participants will receive a single subcutaneous injection of the standard dose of PPSV23 on Day 1.

    Biological: PPSV23 (subcutaneous)

  • Active comparator
    PPSV23 (intramuscular) in Elderly

    Participants will receive a single intramuscular injection of the standard dose of PPSV23 on Day 1.

    Biological: PPSV23 (intramuscular)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants with treatment emergent adverse events (TEAEs) including serious AEs (SAEs), medically attended adverse events (MAAEs), potentially immune mediated medical conditions (PIMMCs) and new onset chronic diseases (NOCDs)

    An adverse event (AE) is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an AE occurring after study immunization to the last visit (up to 30 days post-vaccination if the study is discontinued for an individual subject). An IP-related TEAE is defined as any TEAE with a causal relationship assessed as "yes" by the investigator or subinvestigator.

    Time frame: Up to Day 30

  2. Percentage of participants with vital sign abnormalities and/or adverse events (AEs)

    Percentage of participants with potentially clinically significant vital sign values.

    Time frame: Up to Day 30

  3. Percentage of participants reporting solicited local adverse reactions

    Local reactions include pain, tenderness, erythema/redness, swelling, and induration. The reaction will be graded with 4-range grade: 1 (mild) to 4 (potentially life-threatening).

    Time frame: Up to Day 7

  4. Percentage of participants reporting solicited systemic adverse reactions

    Systemic reactions include nausea, vomiting, diarrhea, headache, fever, fatigue and myalgia and arthralgia. Vital signs up to 7 days postvaccination are collected as systemic reactions. The reaction will be graded with 4-range grade: 1 (mild) to 4 (potentially life-threatening).

    Time frame: Up to Day 7

  5. Percentage of participants with laboratory value abnormalities and/or adverse events (AEs)

    Percentage of participants with potentially clinically significant laboratory values.

    Time frame: Up to Day 30

  6. Percentage of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)

    Percentage of participants with potentially clinically significant ECG values.

    Time frame: Up to Day 30

  7. Percentage of participants with physical exam abnormalities and/or adverse events (AEs)

    Percentage of participants with potentially clinically significant physical exam values.

    Time frame: Up to Day 30

Secondary outcomes

  1. Geometric mean titer (GMT) for opsonophagocytic activity (OPA) for each serotype contained in ASP3772

    OPA measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  2. GMT for OPA for each serotype contained in PPSV23

    OPA measure will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

  3. Ratio of the OPA GMT (each ASP3772 dose level/PPSV23)

    OPA measure will be used to characterize the immunological response on Day 30 after administration of ASP3772 and PPSV23

    Time frame: On Day 30

  4. Geometric mean concentration (GMC) for pneumococcal serotype-specific anticapsular polysaccharide immunoglobulin G (PS IgG) for each serotype contained in ASP3772

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  5. GMC for pneumococcal serotype-specific anticapsular PS IgG for each serotype contained in PPSV23

    PS IgG measure measure will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

  6. Ratio of GMC for pneumococcal serotype-specific anticapsular PS IgG (each ASP3772 dose level/PPSV23)

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772 and PPSV23.

    Time frame: On Day 30

  7. Geometric mean fold rise (GMFR) in anticapsular PS IgG concentration on day 30 relative to pre-immunization contained in ASP3772

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  8. GMFR in anticapsular PS IgG concentration on day 30 relative to pre-immunization contained in PPSV23

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

  9. GMFR in OPA titer on day 30 relative to pre-immunization contained in ASP3772

    OPA titer will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  10. GMFR in OPA titer on day 30 relative to pre-immunization contained in PPSV23

    OPA titer will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

  11. Proportion of subjects with a ≥ 4-fold increase relative to baseline in pneumococcal serotype-specific anticapsular PS IgG concentration for each serotype contained in ASP3772

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  12. Proportion of subjects with a ≥ 4-fold increase relative to baseline in pneumococcal serotype-specific anticapsular PS IgG concentration for each serotype contained in PPSV23

    PS IgG measure will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

  13. Proportion of subjects with a ≥ 4-fold increase relative to baseline in OPA titer for each serotype contained in ASP3772

    OPA titer will be used to characterize the immunological response on Day 30 after administration of ASP3772.

    Time frame: On Day 30

  14. Proportion of subjects with a ≥ 4-fold increase relative to baseline in OPA titer for each serotype contained in PPSV23

    OPA titer will be used to characterize the immunological response on Day 30 after administration of PPSV23

    Time frame: On Day 30

07

Study locations

1 site
  • JP81001
    Fukuoka, Japan
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Nov 2020, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 9, 2020
First posted
Feb 12, 2020
StartActual
Feb 19, 2020
Primary completionActual
Nov 7, 2020
CompletionActual
Nov 7, 2020
Last update
May 2, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04265911
Lead sponsor
Affinivax, Inc.
Responsible party
Sponsor
First posted
Feb 12, 2020
Start date
Feb 19, 2020
Primary completion
Nov 7, 2020
Completion
Nov 7, 2020
Last update
May 2, 2022

Study contacts

Central Contact
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: ASP3772 · 23-valent pneumococcal capsular polysaccharide vaccine

Start the discussion